Table 1.

Comparisons of the relative abundance of 24 tumor-infiltrating immune cells among the 5 subtypes of pituitary adenomas and normal pituitaries

TIICs (%)	Total Pituitary Adenoma (n = 140)	Corticotroph (n = 52)	Somatotroph (n = 16)	Gonadotroph (n = 10)	Lactotroph (n = 5)	NFPA Unspecified (n = 57)	Normal Pituitary (n = 20)	P
B cells	4.12 ± 2.61	5.51 ± 2.55	5.78 ± 2.40	2.37 ± 2.03	4.77 ± 4.23	2.64 ± 1.47	6.15 ± 2.95	0.002
CD4 + T cells	6.29 ± 3.83	3.82 ± 1.98	4.17 ± 3.45	9.00 ± 2.95	4.43 ± 2.93	8.83 ± 3.54	6.30 ± 3.27	0.988
CD8 + T cells	3.15 ± 2.16	4.73 ± 2.17	2.85 ± 1.59	1.58 ± 1.15	3.21 ± 3.03	2.06 ± 1.31	3.37 ± 1.49	0.656
Naïve CD4 + T cells	2.77 ± 3.24	3.27 ± 2.49	8.04 ± 3.72	3.31 ± 1.64	0.84 ± 0.18	0.90 ± 0.19	0.17 ± 0.04	<0.001
Naïve CD8 + T cells	2.18 ± 2.11	2.94 ± 2.14	2.08 ± 1.30	3.31 ± 1.68	1.41 ± 0.74	1.38 ± 2.00	0.96 ± 1.26	0.001
Cytotoxic T cells	4.14 ± 3.27	4.80 ± 2.83	0.50 ± 0.87	1.62 ± 1.53	0.81 ± 1.22	5.30 ± 3.29	4.40 ± 3.71	0.747
Exhausted T cells	0.40 ± 0.94	0.54 ± 1.09	0.52 ± 1.48	0.48 ± 0.71	0.80 ± 0.82	0.18 ± 0.55	1.39 ± 1.90	0.033
T cells regulatory 1	7.21 ± 6.34	4.91 ± 5.57	0	3.84 ± 1.75	6.60 ± 3.13	11.9 ± 5.05	4.00 ± 6.58	0.037
Natural regulatory T cells	3.61 ± 2.85	4.24 ± 2.56	1.40 ± 2.10	0.53 ± 0.64	4.41 ± 5.06	4.11 ± 2.70	3.31 ± 3.55	0.673
Induced regulatory T cells	3.39 ± 3.22	3.32 ± 3.20	2.76 ± 2.46	2.53 ± 1.95	2.35 ± 2.81	3.86 ± 3.61	2.17 ± 2.94	0.113
T-helper 1 cells	4.68 ± 3.43	2.15 ± 1.97	5.77 ± 3.59	5.18 ± 2.41	4.76 ± 4.87	6.59 ± 3.09	3.31 ± 3.78	0.100
T-helper 2 cells	2.74 ± 2.62	2.56 ± 2.71	0.25 ± 0.36	0.33 ± 1.05	4.27 ± 4.07	3.88 ± 2.15	3.88 ± 3.82	0.210
T-helper 17 cells	6.36 ± 4.18	6.86 ± 4.58	6.61 ± 5.15	2.69 ± 3.96	5.03 ± 3.43	6.59 ± 3.29	8.95 ± 6.02	0.016
Follicular T-helper cells	3.14 ± 2.99	1.95 ± 2.25	3.96 ± 3.60	2.20 ± 3.78	5.35 ± 6.31	3.97 ± 2.47	8.38 ± 4.81	<0.001
Central memory T cells	2.78 ± 3.05	4.49 ± 2.94	2.36 ± 2.53	5.15 ± 2.67	0.36 ± 0.47	1.13 ± 2.30	0.17 ± 0.47	<0.001
Effector memory T cells	1.48 ± 1.84	0.28 ± 0.54	2.09 ± 2.43	3.32 ± 2.06	3.14 ± 2.18	1.94 ± 1.73	0.38 ± 0.82	<0.001
Mucosal-associated invariant T cells	4.71 ± 4.46	8.08 ± 4.00	2.57 ± 2.33	4.23 ± 3.11	3.12 ± 4.51	2.47 ± 3.57	3.83 ± 3.75	0.401
Natural killer T cells	3.29 ± 2.75	1.55 ± 1.66	4.38 ± 3.43	5.55 ± 2.66	2.06 ± 1.89	4.29 ± 2.54	3.98 ± 2.35	0.248
Gamma delta T cells	2.49 ± 2.10	2.99 ± 2.12	2.00 ± 1.85	1.08 ± 1.58	2.73 ± 2.52	2.39 ± 2.11	2.59 ± 2.08	0.841
Dendritic cells	7.10 ± 5.40	4.22 ± 2.56	15.77 ± 6.30	11.93 ± 7.78	4.45 ± 3.44	6.67 ± 3.34	6.39 ± 3.44	0.573
Monocytes	7.36 ± 5.32	12.10 ± 4.73	3.22 ± 2.16	3.04 ± 1.12	11.49 ± 2.65	4.59 ± 3.08	3.83 ± 1.89	<0.001
Macrophages	5.63 ± 4.81	5.11 ± 2.57	10.81 ± 7.82	10.77 ± 2.64	3.65 ± 4.56	3.92 ± 3.38	6.21 ± 4.05	0.607
Natural killer cells	5.84 ± 2.95	5.07 ± 2.99	4.72 ± 2.17	7.80 ± 3.48	6.43 ± 5.17	6.47 ± 2.51	13.22 ± 5.36	<0.001
Neutrophils	5.16 ± 3.89	4.51 ± 3.35	7.38 ± 4.09	8.16 ± 1.54	13.52 ± 4.14	3.88 ± 3.14	2.67 ± 2.02	<0.001

The P value indicates the variations between the total pituitary adenoma group and the normal pituitary group. “NFPA Unspecified” refers to clinically NFPAs without the 2017 World Health Organization classification, and this group might consist of silent pituitary adenomas, null cell adenomas, and gonadotroph adenomas.

Abbreviations: NFPA, nonfunctioning PA; PA, pituitary adenoma; TIIC, tumor-infiltrating immune cell.